Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving large and growing markets and unmet medical needs. Our drug development program has yielded a portfolio of pharmaceutical products and candidates with a focus on the treatment of respiratory and central nervous system (CNS) disorders. Our commercialization efforts are carried out by our U.S.-based primary care and specialty-oriented sales forces, as well as through out-licensing partnerships.
We currently commercialize six products in the U.S.: LUNESTA® (eszopiclone); XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler (MDI); XOPENEX® (levalbuterol HCl) Inhalation Solution; BROVANA® (arformoterol tartrate) Inhalation Solution; OMNARIS® (ciclesonide) Nasal Spray; and our most recently launched product, ALVESCO® (ciclesonide) HFA Inhalation Aerosol. We obtained exclusive U.S. distribution rights to OMNARIS Nasal Spray and ALVESCO HFA Inhalation Aerosol from Nycomed GmbH (Nycomed) in January 2008.
Sepracor is also a party to out-licensing agreements that include: Schering-Plough for CLARINEX® (desloratadine); sanofi-aventis for ALLEGRA® (fexofenadine HCl); and UCB Pharma for XYZAL®/XUSALTM (levocetirizine).
We continue to explore new opportunities for growing our pharmaceutical pipeline and our business, and in late 2007 and early 2008, significantly expanded our portfolio through strategic corporate development and licensing agreements. These agreements have provided us with an anti-epileptic candidate, STEDESATM (eslicarbazepine acetate), licensed from BIAL-Portela & Ca, S.A., for which we submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), in March 2009; and Sepracor obtained the rights to three additional ciclesonide product candidates in various stages of development, under the Nycomed agreement, which serve to strengthen our respiratory portfolio.
We continue to broaden our research and development efforts beyond our currently marketed products. Focused primarily on CNS and respiratory disorders, our product candidates are targeted toward the treatment of depression, pain, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis and are in various stages of development ranging from preclinical to Phase III. As part of our future growth strategy, we expect to continue to pursue strategic corporate development and licensing opportunities, which may include in-licensing additional compounds for development and commercialization, co-development and co-promotion collaborations, consideration of appropriate merger and acquisition activities and further expansion of discovery efforts through tactical collaborations.
Our corporate headquarters are located in Marlborough, Massachusetts.